Our strong technology position on synthetic biology, combinatorial biosynthesis, genetic engineering and biocatalysis has enabled identification of novel molecules with uniquely improved properties, and the development of candidate drugs that feed our drug pipeline. The products are natural product hybrids, and oncology is the therapy space for our most advanced candidates.

Natural products are privileged structures designed by nature to interact with many targets. This is especially relevant in cancer, where malignant cells escape death through multiple mechanisms, the main reason for cancer to represent a major unmet medical need today despite many R&D resources dedicated to find new drugs to treat the disease.

Since cancer cells have plenty of mechanisms to escape death, the disease is an ideal target for polypharmacology molecules able to target multiple disease pathways simultaneously. This ability to interact with several drug targets opens the door to new drugs that could avoid the limitations of combination therapies.